WuXi Biologics Signs Agreement with Vertex for Trispecific T-Cell Engager
WuXi Biologics announced that it has signed a license and research service agreement with Vertex Pharmaceuticals for a trispecific T-cell Engager for the treatment of B-cell mediated autoimmune diseases. Under the agreement, Vertex will have exclusive global rights to develop and commercialize an innovative trispecific TCE at the preclinical stage designed for the treatment of B-cell mediated autoimmune diseases. WuXi Biologics will receive an upfront payment and is eligible to receive development, regulatory, and sales milestone payments, as well as royalty payments. In addition, WuXi Biologics will provide Vertex with contract research and development services on novel next-generation TCEs.
